TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years and older in Japan~* Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Life expectancy ≥ 12 weeks.~* Radiographically measurable per RECIST v1.1.~* Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.~Exclusion Criteria:~* Prior receipt of a selective FGFR inhibitor.~* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.~* Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A-ID (Intermittent Dose) Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with FGFR3 mutations or fusions.
- Cohort A-CD (Continuous Dose) Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with FGFR3 mutations or fusions.
- Cohort B Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with other FGF/FGFR alterations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients (18 years)~2. Patients with moderate essential hypertension (untreated must have MSSBP ≥160 and \<180 mmHg at Visit 1, treated must have MSSBP \<180 mmHg at Visit 1) (WHO grade II)~Exclusion Criteria:~1. Severe hypertension(MSDBP ≥110 mmHg or MSSBP ≥ 180 mmHg)~2. Pregnant or nursing women~3. Treated hypertensive patients with controlled hypertension under current therapy (diastolic BP \< 90 mmHg and systolic BP \< 140 mmHg)~4. A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure NYHA II - IV~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 40 years or older as of time of randomization.~* Flagged in KP's databases as having either diabetes or atherosclerotic cardiovascular disease(defined as coronary artery disease, peripheral vascular disease, or a history of atherosclerotic stroke) at the time of randomization~* At least one dispensing of an ACEI, ARB, or statin from a Kaiser Permanente (KP) outpatient pharmacy during the baseline year.~* Suboptimal adherence ((MPR\<0.9) to either statins or ACEI/ARBs during the baseline year~* Continuous membership in KP for the 12 months prior to randomization.~* Qualified for an intervention call at the time of randomization.~Exclusion Criteria:~* Evidence in the electronic medical record (EMR) of allergy or intolerance to statins or ACE inhibitors/ARBs~* medical conditions that would contraindicate use of statins or ACEI/ARBs~* Absence of either a phone number or mailing address in the EMR~* for Kaiser Permanente Hawaii, clinics whose patients tend to fill prescriptions primarily at non-KP pharmacies~* on Kaiser Permanente's do not contact list or in other research studies that could add undue burden

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (UC) (Type: NO_INTERVENTION): Participants in this arm received their usual care with no restrictions.
- Interactive Voice Recognition (IVR) (Type: ACTIVE_COMPARATOR): automated phone calls
- Enhanced IVR (IVR+) (Type: ACTIVE_COMPARATOR): automated phone calls \& Educational mailings and follow-up for nonadherence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study :~Adults 18 years of age or older, who have one of the followings:~* Complicated skin and skin structure infections~* Complicated intra-abdominal infections~* Community-acquired bacterial pneumonia~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~* Patients who have known hypersensitivity to tigecycline~* Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients who have approved indications of Tygacil (Type: None): Approved indications of Tygacil~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LCI699 in Cushing's Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of Cushing's Disease (persistent or recurrent) as evidenced by increased 24-hour urine free cortisol (UFC), normal or increased morning plasma Adrenocorticotropic Hormone (ACTH), and pituitary origin of excess ACTH.~* Patients with de novo Cushing's disease can be included only if they are not considered candidate for surgery~Exclusion Criteria:~* Patients treated with mitotane 6 months prior to Visit 1~* Patients with compression of the optic chiasm~* Patients with a known inherited syndrome as the cause for hormone over secretion~* Patients with Cushing's syndrome due to ectopic ACTH secretion or adrenal Cushing's syndrome~* Patients with pseudo-Cushing's syndrome~* Patients who are not biochemically euthyroid~* Diabetic patients with poorly controlled diabetes (HbA1c \>9%)~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after completion of dosing.~* Patients who have received pituitary irradiation within five years prior to Visit 1.~* Patients with risk factors for QTc prolongation or Torsade de Pointes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part l: Core cohort (Type: EXPERIMENTAL): Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
- Part II Core: Expansion cohort (Type: EXPERIMENTAL): Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
- Part II Core: Follow-up cohort (Type: EXPERIMENTAL): Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Ongoing treatment with metformin on a stable dose of ≥1500 mg/day for at least 12 weeks prior to enrolment~* Inadequate glycemic control, defined as HbA1c ≥6.5% and ≤8.5%~* ≥30 years for males~* ≥55 years for females~Exclusion Criteria:~* Type 1 Diabetes~* Body weight change \>5% within 3 months prior to enrolment~* Renal and liver impairment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Dapagliflozin 10 mg plus Metformin
- B (Type: PLACEBO_COMPARATOR): Placebo plus Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Nocturia ≥2 episodes / night average on the screening diary;~2. Willingness and appropriateness to receive an α- blocker;~3. Willingness to keep a bladder and sleep diary;~4. Willingness to wear a wrist actigraph; and~5. Willingness to make study visits~Exclusion Criteria:~1. Evidence of overt bladder outlet obstruction: peak uroflow \<4 mL/sec on a void of ≥125 mL, or a PVR of ≥ 300 mL;~2. Use of clean intermittent self-catheterization at home or having been instructed by a provider to do so within the last 12 months;~3. Genitourinary cancer, including active prostate cancer with ongoing surgical or radiation treatment, or the need of treatment, or bladder cancer, or persistent unexplained hematuria;~4. Obstructive sleep apnea with CPAP use, provider diagnosis with symptoms, or strong suspicion of diagnosis during screening;~5. Having Parkinson's disease with an uncontrolled tremor (invalidates wrist actigraphy);~6. Poorly controlled congestive heart failure as evidenced on physical examination;~7. Poorly controlled diabetes mellitus with either hemoglobin A1c of ≥ 7.5 or a random glucose ≥ 200 within last 3 months; or~8. Unstable health conditions expected to result in death or hospitalization within 3 months, as assessed by PI or Site PI;~9. Previously receiving intensive bladder training;~10. Allergic to Tamsulosin;~11. Previous spinal cord injury;~12. Currently on dialysis or in consideration for dialysis due to end stage renal disease;~13. More than 2 urinary tract infections within the last 12 months;~14. Not able to transfer independently from a wheelchair to the toilet;~15. Unstable dose of diuretic within the past 3 months;~16. Has an artificial urinary sphincter;~17. Impaired mental status;~18. TURP or other urologic surgery within the last 6 months.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Behavioral and Exercise Therapy (M-BET) (Type: EXPERIMENTAL): Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
- Drug Therapy w/ Behavioral Placebo (Type: ACTIVE_COMPARATOR): alpha-adrenergic antagonist medication with a placebo behavioral intervention
- Combination Therapy (Type: ACTIVE_COMPARATOR): Combination therapy: MBET and alpha-adrenergic antagonist medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Cognitive Screening in Older Spinal Surgical Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients 70 years of age and older presenting to the BWH Weiner Center for Preoperative Evaluation~* undergoing elective spine surgery~Exclusion Criteria:~* include planned ICU admission postoperatively~* history of stroke or brain tumor~* uncorrected vision or hearing impairment (unable to see pictures or read or hear instructions)~* limited use of the dominant hand (limited ability to draw)~* inability to speak, read, or understand English.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- older surgical patients (Type: None): Older surgical patients presenting for elective spine surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be scheduled for trans-jugular liver biopsy the day of the ultrasound procedure.~* Be at least 21 years of age.~* Be medically stable.~* If a female of child-bearing potential, must have a negative pregnancy test.~* Be conscious and able to comply with study procedures.~* Have read and signed the IRB-approved Informed Consent form for participating in the study.~Exclusion Criteria:~* Females who are pregnant or nursing.~* Patients not scheduled for trans-jugular liver biopsy~* Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h afterwards,.~* Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts~* Patients with pulmonary hypertension or unstable cardiopulmonary conditions~* Patients currently on chemotherapy or with other primary cancers requiring systemic or hepatic loco-regional treatment.~* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:~* Patients on life support or in a critical care unit.~* Patients with unstable occlusive disease (e.g., crescendo angina)~* Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.~* Patients with uncontrolled congestive heart failure (NYHA Class IV)~* Patients with recent cerebral hemorrhage.~* Patients who have undergone surgery within 24 hours prior to the study sonographic examination.~* Patients with a history of anaphylactic allergy to eggs or egg products, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock. (Subjects with nonanaphylactic allergies to eggs or egg products may be enrolled in the study, but must be watched carefully for 1 h following the administration of SONAZOID).~* Patients with congenital heart defects.~* Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli.~* Patients with respiratory distress syndrome~* Patients with thrombosis within the hepatic, portal, or mesenteric veins.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SHAPE measurement (Type: EXPERIMENTAL): 48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Using Mobile Applications for Improving Oral Hygiene

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants were having orthodontic fixed appliance treatment.~2. Participants were aged 12 years old and above, owned mobile phones and did not have mental or physical disabilities.~3. Participants were willing to comply with given oral hygiene instructions.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mobile phone application (Type: EXPERIMENTAL): Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
- Verbal oral hygiene instructions (Type: ACTIVE_COMPARATOR): Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known (angiographically documented) CAD.~* On maintenance treatment with aspirin (81 mg per day) for at least 1-month as per standard of care.~* Type 2 DM on treatment with oral hypoglycemic agents and/or insulin.~* Age between 18 and 74 years old.~Exclusion Criteria:~* History of stroke, transient ischemic attack or intracranial bleeding.~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor).~* Known allergies to aspirin, ticlopidine, clopidogrel, prasugrel, ticagrelor.~* Weight \<60kg.~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran).~* Blood dyscrasia or bleeding diathesis.~* Platelet count \<80x106/mL.~* Hemoglobin \<10 g/dL.~* Active bleeding or hemodynamic instability.~* Creatinine Clearance \<30 mL/minute.~* Baseline ALT \>2.5 times the upper limit of normal.~* Hb A1c ≥ 10 mg/dL within 3 months.~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~* Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant females\*.~  * Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel first, then ticagrelor (Type: ACTIVE_COMPARATOR): Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
- Ticagrelor first, then prasugrel (Type: ACTIVE_COMPARATOR): Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete